SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China
Published March 11, 2026 · Recall initiated: October 20, 2025
Summary
FDA records drug Class I recall D-0388-2026, published March 11, 2026 and initiated October 20, 2025. Recalling firm: ANTHONY TRINH, 123Herbals LLC; Status: Ongoing; Reported quantity: N/A; Lot: All lots within expiry. Class I means a reasonable probability of serious adverse health consequences or death.
Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.
What's the hazard
Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.
What to do
Voluntary: Firm initiated · Press Release
Get an email when a new FDA recall like this is published
Free. We only write when there's a new recall that matches. Unsubscribe in one click.
Recall details
- Manufacturer
- ANTHONY TRINH, 123Herbals LLC
- Distributor
- USA nationwide
- Lot
- All lots within expiry
- Risk classification
- Class I
- Area (FDA)
- drug
- Country
- United States
Related recalls
- FDAMAXIMUM, ZONE 2, 4% Lidocaine Cream, (Lidocaine 4% and Epinephrine 0.01%), 1 oz bottles, Distributed By:March 11, 2026
- FDASodium Iodide (I-131) Solution, Therapeutic Oral, packaged as a) 1 ml V-vial, NDC 69208-003-15; Order 49317,March 11, 2026
- FDAMAXIMUM, ZONE 1, 4% Lidocaine Cream, 1/2 oz bottles, Distributed By: Dermal Source, Portland, OR 97232, NDCMarch 11, 2026
- FDASemaglutide Inj, 2mg x 10, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe,March 11, 2026
- FDAFIVE-STAR, VASOCAINE Spray, (Lidocaine HCl 4%, Racepinephrine HCl 0.01%), 4oz bottles, Distributed By: DermalMarch 11, 2026
- FDASemaglutide Inj., 2 mg x 5, Sterile Multi-Dose Vial, Rx only, Nomida, 25055 W Valley Pkwy, Suite 106, Olathe,March 11, 2026
Questions about this recall
Was SILINTAN 25/pills, packaged in a 25-count bottle, Shanghai Chinese Medical Works, Shanghai, China recalled?
Yes. FDA published recall D-0388-2026 on March 11, 2026. Reported hazard: Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared meloxicam.
What should I do if I have this product?
Voluntary: Firm initiated · Press Release